DA Davidson analyst Linda Bolton Weiser lowered the firm’s price target on Beauty Health to $16.50 from $35 but keeps a Buy rating on the shares after its Q2 results. Earnings missed and the company disclosed technical issues with the first Syndeos launched in the U.S., resulting in refurbished Elite sales and lower system selling prices, but sales and EBITDA exceeded estimates, the analyst tells investors in a research note. Syndeo issues in the U.S. should be completely remedied by early Q4, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SKIN:
- The Beauty Health (NASDAQ:SKIN) Glows On Healthy Q2 Numbers
- Beauty Health backs FY23 revenue view $460M-$480M, consensus $461.57M
- Beauty Health reports Q2 EPS 3c, consensus 5c
- Beauty Health CFO Liyuan Woo leaves, Michael Monahan succeeds
- Short Report: Carvana short squeeze sends bearish position to 2023 lows